440 filings
Page 5 of 22
8-K
d3mfwipirsy9ry yrbc
10 Nov 21
Hepion Pharmaceuticals Announces Poster Details for the Upcoming AASLD The Liver Meeting® 2021
9:41am
8-K
e76z3 b1m08nt
8 Oct 21
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
xjyct7jn1vymka
7 Oct 21
Hepion Pharmaceuticals to Participate in the H.C. Wainwright 5th Annual NASH Investor Conference
4:24pm
8-K
7c53kz1o
30 Sep 21
A BETTER APPROACH TO DRUG DEVELOPMENT FOR LIVER DISEASES October 202 1 | INVESTOR PRESENTATION smart drug smart technology smart development
5:22pm
8-K
cpwihhhar4b 5wl40z
29 Sep 21
Other Events
9:22am
8-K
1kax9w6ncyoqd4flj3
13 Sep 21
Regulation FD Disclosure
8:28am
8-K
gm5arq17wefridr8 12k
23 Aug 21
Amendments to Articles of Incorporation or Bylaws
9:19am
8-K
mcsx5b95aw0
26 Jul 21
Hepion Pharmaceuticals Announces Postponement of 2021 Annual Meeting of Stockholders
12:00am
8-K
7lliu9hqunckt7
13 Jul 21
Hepion Pharmaceuticals Announces Positive Topline Data from Phase 2a ‘AMBITION’ NASH Trial; All Primary Endpoints Achieved
10:38am
DEFA14A
5y974htngojx
25 Jun 21
Additional proxy soliciting materials
4:48pm
8-K
slwrp0psm3yirk
25 Jun 21
Hepion Pharmaceuticals Announces Adjournment of Annual Meeting
4:46pm
8-K
51170 c81gb
9 Jun 21
Hepion Pharmaceuticals to be Added to the Russell Microcap® Index
9:06am
8-K
tswwp 72m2g
6 May 21
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
10:14am
8-K
bvqab67bthkjwqn069
29 Apr 21
Hepion Pharmaceuticals Presents Machine Learning “Learn and Confirm” Modeling Strategy at 4th Global NASH Congress
10:07am